Table 1. Cell cycle inhibitors in ongoing clinical trials in MM.

Name	Target	Development status
Cdk inhibitors
Flavopiridol	Cdk 1,2,4,6 & 7	Phase II
SNS-032	Cdk 2,7 & 9	Phase I
AT7519	Cdk 1,2,4,6,7 & 9	Phase I/II
Dinaciclib	Cdk 1,2,5 & 9	Phase I/II
Palbociclib	Cdk 4/6	Phase I/II
P276-00	Cdk 4–cyclin D	Phase I/II
Microtubule targeting agents
Vincristine	tubulin	FDA approved
Paclitaxel	tubulin	Phase II
CYT997	tubulin	Phase II
Motor protein targeting agents
Filanesib	kinesin protein Eg5	Phase II
Aurora kinase inhibitors
ENMD-2076	Aurora A, B & C kinase	Phase I
AT9283	Aurora A, B & C kinase	Phase II
Alisertib	Aurora A kinase	Phase I